WL

Wolfgang Link

Consejo Superior de Investigaciones Científicas, Universidade do Algarve Centro de Investigação em Biomedicina, Universität Hamburg, Universidade do Algarve

ORCID iD 0000-0002-3340-5165
Follow

About

Dr Link is a CSIC researcher focussed on molecular mechanisms cancer and aging. He is co-founder of Refoxy Pharma GMBH, a biotech company dedicated to develop pharmaceuticals to target FOXO proteins. Dr Link counts with more than 25 years of experience in basic and translational biomedical research, and has been an independent researcher for over 15 years. He holds three patents (one licensed to Sanofi), published three books, three book chapters and over 90 articles (4 more under revision), 10 as first author, over 40 as senior author. He published articles (selection) in Nature, Oncogene, Drug Resistance Updates, PNAS, Nature Reviews Drug Discovery, Trends in Biotechnology, EMBO J, The Lancet Oncology and Aging Cell. His work has been cited 5914 times. He also serves as an editorial board member of prestigious, international peer reviewed journals including Cancers, Frontiers in Oncology and Frontiers in Cell and Developmental Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link acts as an expert evaluator for funding organisations including ERC (EU), The Brain Tumour Charity (UK), Leuka (UK), Dutch Cancer Society (Netherlands), Austrian Science Fund (ASF, Austria), ANEP (Spain), FCT (Portugal), MOH (Italy), AIFA (Italy), University of Macau (China), HRC (New Zealand). He also serves as a peer-reviewer for (selection) Carcinogenesis, Chemical Reviews, Drug Discovery Today, FEBS Letters, Hepatology, International Journal of Cancer, J Cell Science, Nature Chemical Biology, Nature Comm., Oncogene, PloS ONE, PNAS, Scientific Reports, Trends in Cell Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019).
He obtained his PhD degree in molecular neuroscience from the University of Hamburg, followed by a short postdoc at CNB (Madrid), before joining the pharma/biotech company EleGene AG (Martinsried, Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted head of drug screening in 2010. In 2011, he accepted a position as assistant professor at the faculty of Biomedical Sciences and Medicine (University of Algarve, Portugal) where he was head of the Department of Oncobiology and director of a Master´s program on Molecular Mechanisms of Cancer. He has supervised 7 Post-doctoral fellows, 4 PhD students, 15 Master students. Dr Link is a leading expert in High Content Screening technology and the biology of FOXO and Tribbles proteins.

Employment

  • Consejo Superior de Investigaciones Científicas Group leader
    2018 - Present
  • Universidade do Algarve Centro de Investigação em Biomedicina Head of Department
    2014 - 2018
  • Universidade do Algarve Assistant Professor
    2011 - 2018
  • Centro Nacional de Investigaciones Oncológicas Head of screening section
    2010 - 2011
  • Centro Nacional de Investigaciones Oncológicas Senior scientist
    2001 - 2010
  • EleGene AG Research scientist
    2000 - 2001
  • Centro Nacional de Biotecnología Postdoctoral fellow
    2000 - 2000

Education

  • Universität Hamburg PhD
    1995 - 2000
  • Universität Hamburg Diplom
    1994 - 1995
  • Universität Hamburg
    1987 - 1994

Projects & Funding

Projects & funding information is unavailable.

Publications (155)